Check-Cap (NASDAQ:CHEK) Earns Sell Rating from Analysts at StockNews.com

StockNews.com initiated coverage on shares of Check-Cap (NASDAQ:CHEK) in a research note published on Thursday morning. The firm issued a sell rating on the medical research company’s stock.

Check-Cap Price Performance

NASDAQ CHEK opened at $0.59 on Thursday. Check-Cap has a 1 year low of $0.56 and a 1 year high of $3.45. The stock has a market capitalization of $3.45 million, a PE ratio of -0.20 and a beta of 0.25. The business’s 50-day moving average is $0.95 and its 200 day moving average is $1.56.

Check-Cap Company Profile

Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based screening technology that utilizes ultra-low-dose X-rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule for detection of suspected polyps; C-Scan Track, a disposable system attached to the patient's back through biocompatible adhesive skin patches; and C-Scan View software, a client/server-based application that enables procedure data download from the C-Scan Track, data analysis, and report generation.